Clinical Scorecard: Evaluating Serum TRACP5b as a Diagnostic Marker for Secondary Osteoporosis in Ankylosing Spondylitis: A Comparative Cross-Sectional Analysis with Primary Osteoporosis and Healthy Controls

At a Glance

Key Highlights

• Osteoporosis is classified as primary or secondary, with ankylosing spondylitis causing secondary osteoporosis via inflammation-driven bone loss.
• DXA is the gold standard for BMD assessment but does not capture dynamic bone turnover; TRACP5b is a specific biomarker reflecting osteoclast activity and bone resorption.
• Serum TRACP5b levels may provide complementary diagnostic and monitoring value in AS-related secondary osteoporosis beyond DXA measurements.

Guideline-Based Recommendations

Diagnosis

• Use DXA to assess bone mineral density and diagnose osteoporosis (T-score ≤ −2.5).
• Consider serum TRACP5b measurement as a biomarker reflecting osteoclast activity and bone resorption in AS patients.
• Exclude other secondary causes of osteoporosis unrelated to AS before diagnosis.

Management

• Monitor disease activity in AS using clinical indices such as BASDAI alongside bone health assessments.
• Incorporate biomarker data (e.g., TRACP5b) to guide therapeutic decisions targeting bone remodeling and inflammation.

Monitoring & Follow-up

• Regularly assess BMD via DXA at lumbar spine, femoral neck, and wrist.
• Measure serum TRACP5b levels to monitor osteoclast activity and bone resorption dynamics in AS patients.

Risks

• Recognize increased fracture risk associated with reduced BMD and elevated TRACP5b levels in AS and osteoporosis patients.
• Be aware of confounding factors such as renal function, which does not affect TRACP5b levels.

Patient & Prescribing Data

Adults with ankylosing spondylitis and primary osteoporosis undergoing evaluation for bone health.

Serum TRACP5b can serve as a biomarker to assess bone resorption activity and may help tailor osteoporosis management in AS beyond standard DXA measurements.

Clinical Best Practices

• Perform comprehensive clinical evaluation including history, physical examination, and disease activity scoring (e.g., BASDAI) in AS patients.
• Use DXA scanning at standard anatomical sites for quantitative BMD assessment.
• Incorporate serum TRACP5b measurement via ELISA as a complementary tool to evaluate bone resorption and osteoclast activity.
• Exclude other autoimmune, connective tissue diseases, and secondary osteoporosis causes unrelated to AS before diagnosis.
• Apply appropriate statistical and diagnostic criteria (e.g., ROC curve analysis) to interpret TRACP5b levels in clinical context.

References

• World Health Organization osteoporosis definition and guidelines
• Modified New York criteria for ankylosing spondylitis diagnosis
• Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)